Newsroom | 2778 results

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture...

DUBLIN--(BUSINESS WIRE)--The "GCC Online Pet Care Services Market Size, Platforms, Consumer Segments & Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The GCC Online Pet Care Services Market, valued at USD 1.2 billion, has experienced notable growth, driven by rising pet ownership and increasing disposable incomes, coupled with a preference for online shopping. Countries like the UAE and Saudi Arabia dominate this market, particularly in urban centers such as Dubai...

MOORPARK, Calif.--(BUSINESS WIRE)--Kennel Connection donated $2,500 to Frankie’s Friends, doubled to $5,000, to support pets in need this Giving Tuesday....

PLANTATION, Fla.--(BUSINESS WIRE)--Chewy, Inc. (NYSE: CHWY) (“Chewy”), a trusted destination for pet parents and partners everywhere, has released its financial results for the third quarter of fiscal year 2025 ended November 2, 2025. Fiscal Q3 2025 Highlights: Net sales of $3.12 billion increased 8.3 percent year over year Gross margin of 29.8 percent increased 50 basis points year over year Net income of $59.2 million, including share-based compensation expense and related taxes of $76.5 mill...

トロント--(BUSINESS WIRE)--（ビジネスワイヤ） -- SoluPetは、データと科学に基づきペットの認知面の健康に特化し、シニア犬の認知機能の加齢を支えるソリューションを開発している企業です。このたび、同社はアジア最大級の上場ヘルスケア企業の1つであるCHCとの戦略的パートナーシップを発表しました。CHCは1,600人以上の従業員を擁し、病院、薬局、獣医療機器、動物病院など多岐にわたる事業を展開しており、SoluPetの主力製剤 Neuronal Defense ™を消費者直接取引のパイロットとして台湾に導入します。 本パートナーシップは、SoluPetにとってアジア太平洋地域への初進出となり、イヌの認知機能の加齢（canine cognitive aging：CCA）に対応する、信頼性が高く科学的裏付けのあるソリューションへの世界的なニーズの高まりとも合致しています。台湾は、世界第3位の規模を誇るペットケア市場を持ち、Neuronal Defense™のようなサイエンスドリブンな製品のローンチ先として理想的な市場です。イヌの長寿化とペットと暮らす世帯の増加に伴い、...

多倫多--(BUSINESS WIRE)--(美國商業資訊)-- SoluPet運用數據和科學為高齡犬開發先進的老化補給品，增進寵物認知健康。該公司今天宣布與CHC（承業生醫企業集團）達成一項合作關係 。CHC是亞洲規模數一數二的公開上市醫療保健公司，員工數在1600人以上，營運範圍涵蓋醫院、藥房、獸醫醫療器械和動物保健診所。CHC將推出一項面向消費者的試行計畫把SoluPet的旗艦配方產品 Neuronal Defense ™引介到台灣。 這項合作關係為SoluPet擴大到亞太地區跨出第一步，並滿足全球對有科學依據的犬類認知老化 (CCA) 可靠解決方案不斷高升的需求。台灣的寵物照護市場全球排名第三，使它成為首推像是Neuronal Defense™這類科學產品的理想地區。有鑑於犬類的壽命延長，而且豢養寵物的家庭越來越多，CCA成了困擾全球高齡寵物的一大問題。Neuronal Defense™的配方採用符合美國食品藥物管理局一般公認安全物質 (FDA GRAS) 標準的的專利活性成分，並有十多年來以數據推動的研究成果支持，說明SoluPet致力提升高齡犬認知支援標準的決心。 「與CH...

多伦多--(BUSINESS WIRE)--(美国商业资讯)-- SoluPet是一家以数据和科学为驱动的宠物认知健康公司，致力于为老年犬开发先进的认知老化支持方案。该公司今日宣 布与亚洲最大的上市医疗保健集团之一CHC达成战略合作。CHC拥有超过1,600名员工，业务涵盖医院、药房、兽用医疗器械和动物诊所。此次合作将通过直接面向消费者的试点项目，在台湾推广SoluPet的旗舰产品 Neuronal Defense ™。 此次合作标志着SoluPet首次进军亚太地区，也契合了全球对可靠、科学的犬类认知老化（CCA）解决方案日益增长的需求。台湾是全球第三大宠物护理市场，也是推出Neuronal Defense™等科学驱动型产品的理想首发市场。随着犬只寿命延长和宠物家庭数量的增加，CCA对全球老年宠物的影响日益加剧。Neuronal Defense™采用SoluPet独有的FDA GRAS（公认安全）活性成分配方，并有着十余年的数据驱动研究支持，体现了SoluPet致力于提升老年犬认知支持标准的承诺。 “与CHC的合作使SoluPet能够为宠物健康领域最紧迫的挑战之一——认知老化，提供科学...

NEW YORK--(BUSINESS WIRE)--Working pet parents take an average of 7.3 days off work annually for pet health issues, according to new findings from Wagmo, the pet healthcare benefit trusted by leading employers. The second annual Working Pet Parent Survey, which polled 1,017 full-time U.S. employees with cats or dogs, reveals that pet health has become a significant workplace productivity issue, with three-quarters of respondents reporting effects on job performance. Seventy-five percent of work...

TORONTO--(BUSINESS WIRE)--SoluPet, the data and science-driven pet cognitive health company developing advanced cognitive-aging support for senior dogs, today announced a strategic partnership with CHC, one of Asia’s largest publicly traded healthcare organizations. CHC - with more than 1,600 employees and operations spanning hospitals, pharmacies, veterinary medical devices, and animal health clinics - will introduce SoluPet’s flagship formulation, Neuronal Defense™, into Taiwan through a dire...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well...